This resistance was not attributable to the acquired mutations in SMO but rather to intra-tumor heterogeneity and additional mutations in critical driver genes, including TP53, APC, FGFR1 and NOTCH1, which likely enable HH pathway inhibition. The gene discussed is TP53; the disease is neoplasm.